Novo Nordisk A/S Common Stock (NVO)

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending.

Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from retail traders.

Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move orchestrated by its top investor, the non-profit Novo Nordisk Foundation. The shake-up, which will see seven independent board members, including the chairman, step

The rapid growth rates of recent years aren't guaranteed to continue.

Don't try to catch a falling surgical knife.

The tides continue to change in Eli Lilly's favor in the GLP-1 space.

That's plenty of time for these drugmakers to move past their challenges.

These companies are jockeying for position in a potential $150 billion market opportunity.

Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday.

Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.

Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs.

The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.

While Dow Jones futures were down by 0.13% at the time of writing, the S&P 500 futures declined 0.41%.

These stocks have climbed in the triple digits over the past few years.

Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks.

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.